High-Dose Cyclophosphamide in Highly Refractory Multiple Myeloma Patients As a Bridge to Further Novel Therapies

被引：3
|
作者：
Nikonova, Anna [1 ]
Caplan, Stephen N. [2 ]
Shamy, April [2 ]
Gyger, Martin [2 ]
机构：
[1] Univ Toronto, Princess Margaret Hosp, Toronto, ON, Canada
[2] McGill Univ, Jewish Gen Hosp, Montreal, PQ, Canada
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.5676.5676
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5676
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Treatment of refractory myasthenia: "Rebooting" with high-dose cyclophosphamide
    Drachman, DB
    Jones, RJ
    Brodsky, RA
    ANNALS OF NEUROLOGY, 2003, 53 (01) : 29 - 34
  • [32] High-dose cyclophosphamide for refractory autoimmune hemolytic anemia
    Moyo, VM
    Smith, D
    Brodsky, I
    Crilley, P
    Jones, RJ
    Brodsky, RA
    BLOOD, 2002, 100 (02) : 704 - 706
  • [33] TIMED-SEQUENTIAL HIGH-DOSE CYCLOPHOSPHAMIDE AND VINCRISTINE IN THE TREATMENT OF MULTIPLE-MYELOMA
    LENHARD, RE
    KALISH, LA
    OKEN, MM
    ETTINGER, DS
    GLICK, J
    CANCER, 1994, 73 (08) : 2113 - 2118
  • [34] T CELL REPLETE HAPLOIDENTICAL TRANSPLANTATION FOR REFRACTORY MULTIPLE MYELOMA USING NONMYELOABLATIVE CONDITIONING AND HIGH-DOSE POST TRANSPLANT CYCLOPHOSPHAMIDE
    Bramanti, S.
    Vai, A.
    El Cheikh, J.
    Furst, S.
    Crocchiolo, R.
    Sarina, B.
    Harbi, S.
    Granata, A.
    Mauro, E.
    Carlo-Stella, C.
    Santoro, A.
    Stoppa, A. M.
    Blaise, D.
    Castagna, L.
    BONE MARROW TRANSPLANTATION, 2014, 49 : S352 - S352
  • [35] Idarubicin, melphalan and cyclophosphamide:: an intensified high-dose regimen for the treatment of myeloma patients
    Heyll, A
    Söhngen, D
    Kobbe, G
    Schneider, P
    Bauser, U
    Thiele, KP
    Wehmeier, A
    Südhoff, T
    Quenzel, EM
    Rieth, C
    Wernet, P
    Fischer, J
    Frick, M
    Aul, C
    LEUKEMIA, 1997, 11 : S32 - S34
  • [36] Frail elderly patients with relapsed-refractory multiple myeloma: efficacy and toxicity profile of the combination of bortezomib, high-dose dexamethasone, and low-dose oral cyclophosphamide
    Mele, Giuseppe
    Giannotta, Angela
    Pinna, Salvatore
    Loseto, Giacomo
    Coppi, Maria Rosaria
    Brocca, Claudio Maurizio
    Melpignano, Angela
    Quarta, Giovanni
    LEUKEMIA & LYMPHOMA, 2010, 51 (05) : 937 - 940
  • [37] Multicenter phase II feasibility trial of high-dose tamoxifen in patients with refractory or relapsed multiple myeloma
    Decaudin, D
    Etienne, MC
    de Cremoux, P
    Maciorowski, Z
    Vantelon, JM
    Voog, E
    Urien, S
    Tran-Perennou, C
    Renée, N
    Vielh, P
    Némati, F
    Pouillart, P
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (08) : 636 - 637
  • [38] Phase II multicenter trial of high-dose tamoxifen in patients with refractory or relapsed multiple myeloma.
    Decaudin, D
    Etienne, MC
    de Cremoux, P
    Maciorowski, Z
    Vantelon, JM
    Voog, E
    Urien, S
    Tran-Perennou, C
    Némati, F
    Védrine, L
    Vielh, P
    Pouillart, P
    BLOOD, 2003, 102 (11) : 208B - 208B
  • [39] Cardiac Toxicity of High-Dose Cyclophosphamide in Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation
    Samo Zver
    Vesna Zadnik
    Matjaz Bunc
    Polona Rogel
    Peter Cernelc
    Mirta Kozelj
    International Journal of Hematology, 2007, 85 : 408 - 414
  • [40] High-Dose Cyclophosphamide in the Treatment of Multiple Sclerosis
    Schwartzman, Robert Jay
    Simpkins, Nicole
    Alexander, Guillermo M.
    Reichenberger, Erin
    Ward, Kristine
    Lindenberg, Noah
    Topolsky, David
    Crilley, Pam
    CNS NEUROSCIENCE & THERAPEUTICS, 2009, 15 (02) : 118 - 127
12345